Clinical trial and special access supply · Planned
Precisely dosed psychedelic medicines for research and access programs.
PharmaTher intends to become a reliable supplier of precisely dosed, 3D printed psilocybin and MDMA to researchers, trial sponsors and access programs, through licensed GMP partners.
Access is opening
Patients can already reach these medicines through regulated programs.
Health Canada Special Access Program
Eligible patients can access psilocybin and MDMA through the Special Access Program, reopened to restricted drugs in January 2022.
Authorised Prescriber Scheme
Authorised psychiatrists can prescribe psilocybin and MDMA to eligible patients.
2026 executive order
Directs the FDA and the Drug Enforcement Administration to create a pathway for eligible patients to access investigational psychedelic drugs under the Right to Try Act.
What trials and access programs need
Small GMP batches, several strengths and matching placebos.
Clinical trials and access programs need consistent doses in several strengths, in batches far smaller than a conventional production run, plus placebos that match the active product. That is what pharmaceutical 3D printing does well.
Program build-out, 2027–2028
Researchers, trial sponsors and access programs can talk to us now about future supply.
Discuss supplySee the full pipeline
Five areas where a precise dose, a combination or a small batch makes a medicine possible.
Pipeline overviewPsilocybin and MDMA are Schedule I controlled substances in the United States and are controlled in Canada and other jurisdictions. They are not approved for any medical use by the FDA, and their manufacture, supply and use require licences and authorizations from the DEA, Health Canada and other regulators. Access pathways may change. Plans and timelines are internal estimates and forward-looking.